Full enrollment in adult and adolescent SAFEGUARD cohorts sets up a pivotal 2027 data readout.
SABS SAB Biotherapeutics, Inc. Common Stock
XNAS
3.11
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
SABS
$3.11
—
What changed
Recent filings, trades and movesKey stats
$3.11
- 52-Week Range
- $2.44 – $5.15
- YTD
- -17.51%
- IV Rank (30D)
- 20.79
- Straddle Price
- $8.72
- P/C Vol Ratio
- 0.51
- Market Cap
- $0.3B
- Open
- $3.10
- Day Range
- $3.05 – $3.18
- Volume
- 270,970
- Prev Close
- $3.03
Fair Value
MODEL: LONG
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.90% |
| Beta vs SPY | 1.25 |
| Cost of Equity (CAPM) | 11.79% (VRP-adj) |
| WACC | 11.75% |
| Volatility Risk Premium | +71.8pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +3.0% |
| DCF Horizon | 5 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.03 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.1B |
| Return on Equity (TTM) | -18.1% |
| Book / Price | 88.9% — banking bias active (P/B is primary) |
| Debt / Equity | 0.01 |
| Quality Score | 1/6 — cyclical/struggling (5y DCF) |
| SMA 50 | $3.19 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $2.93 |
| Bollinger Width / SMA20 | 35.0% (drives anchor stability) |
| Net Debt | $-0.0B |
| Market Cap | $0B |
Peers used for multiples: ABEO, CLDX, DCTH
(filtered from 8 ETF-co-members; sector bias active)
60-Day Conviction
90%
20-Day Fair Value
≈ by Dec 8, 2026
$3.13
α +1.1%
rank 89%
conviction
70%
40-Day Fair Value
≈ by Jan 6, 2027
$3.30
α +6.5%
rank 90%
conviction
99%
60-Day Fair Value
≈ by Feb 4, 2027
$3.26
α +5.2%
rank 81%
conviction
90%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | |
| Peer EV/EBITDA | n/a | 0% | |
| Peer P/B | $8.38 | 24% | median 3.1× · 3 peers |
| Peer P/S | n/a | 0% | median 8.8× · 3 peers |
| Market Anchor (SMA50) | $3.19 | 76% | stability 60% (BB-width) |
| Options Expected (B-L 30d) | n/a | 0% |
As of 2026-11-09 · updated
Related
About
- Industry (SIC)
- BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836) · industry map
- Exchange
- XNAS
- Market Cap
- $0.3B
- Employees
- 86
- List Date
- 2021-10-22
- CIK
- 0001833214
- Last Earnings
- Mar 29
- Headquarters
- Miami Beach, FL
- Homepage
- https://www.sab.bio
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potenti…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | -- | -31.65% | 4.52% | -14.29% | -40.97% | 16.45% | -13.19% |
| Feb | -- | -15.07% | -7.29% | -24.41% | -20.47% | -6.39% | -14.73% |
| Mar | -- | -18.08% | -32.76% | 2.95% | -12.82% | -5.90% | -13.32% |
| Apr | -- | -27.75% | 93.18% | 0.00% | 38.19% | -3.36% | 20.05% |
| May | -- | -18.33% | 1.14% | -35.61% | 13.53% | 3.75% | -7.10% |
| Jun | -- | -25.26% | -8.79% | 16.10% | -8.59% | 13.37% | -2.63% |
| Jul | -- | -22.30% | -2.41% | -8.71% | 6.82% | -7.99% | -6.92% |
| Aug | -- | -35.77% | -15.29% | 6.14% | -6.73% | -2.11% | -10.75% |
| Sep | -- | -1.68% | -14.10% | -7.82% | -5.19% | -14.32% | -8.62% |
| Oct | 8.36% | 20.02% | 51.50% | 25.38% | 64.14% | 9.48% | 29.81% |
| Nov | 29.18% | 12.50% | -2.79% | -24.74% | 21.54% | -5.91%* | 4.96% |
| Dec | -30.52% | -43.28% | -26.86% | 35.02% | -1.32% | -- | -13.39% |
| Total | -2.74% | -92.12% | -11.18% | -43.26% | 9.15% | -7.31% | -24.58% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $2.94
SMA 50: $3.18
SMA 200: $3.65
Current: $3.10
EMA 12: $3.07
EMA 26: $3.06
MACD: 0.0064 | Signal: 0.0273
BEARISH
ADX (14): 19.24
RANGE
+DI: 17.29
−DI: 19.06
Momentum Oscillators
RSI (14): 51.18
NEUTRAL
Stoch %K: 53.71
Stoch %D: 60.73
Williams %R: -47.24
Volume & Volatility
BB Upper: $3.45
BB Lower: $2.42
NEUTRAL
OBV: 95,646,606
Vol SMA 20: 604,742
Vol ROC: -16.69%
ATR: $0.22
True Range: $0.15
HV 20: 86.1%
HV 30: 76.4%
HV 60: 59.7%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-11-08T00:00:00 – 2026-11-06T00:00:00
AI Analysis
LLM Stock Analysis Report: SABS
Executive Summary
BULLISH (Confidence Level: 8/10)
Key Drivers:
- Strong technical signals, including a bullish MACD crossover and rising RSI
- Positive news sentiment, with recent headlines focused on the company's financial performance and product developments
Primary Risks:
- High volatility, which may lead to significant price movements
- Potential for increased regulatory scrutiny or negative market reactions to upcoming earnings releases
Investment Thesis: SABS presents a compelling investment opportunity due to its strong technical momentum, positive news sentiment, and potential for future growth.
Recent News Sentiment Impact: The recent surge in news headlines with positive sentiment has contributed to the stock's upward movement. This trend is likely to continue as long as the news flow remains favorable.
Technical Analysis
Trend Direction: Short-term: Uptrend (1-4 weeks), Medium-term: Uptrend (1-3 months), Long-term: Uptrend (3-12 months)
Support/Resistance Levels:
- SMA 20: $3.68 (resistance)
- SMA 50: $3.70 (resistance)
- SMA 200: $3.78 (support)
- Upper Bollinger Band: $3.96
Momentum Signals:
- RSI interpretation: Neutral (51.98), indicating a lack of overbought or oversold conditions
- MACD signal: Bullish crossover, supporting the uptrend
- Bollinger Bands position: Squeeze, indicating potential for continued price movement
Volume Analysis: Volume is increasing, with an average volume flow of 452704.43. On-Balance Volume (OBV) is also rising, indicating accumulation.
News & Sentiment Analysis
Recent Headlines Summary:
The recent news headlines have been overwhelmingly positive, focusing on the company's financial performance and product developments.
Sentiment Assessment: Positive
Catalyst Identification:
- Upcoming Investor Conferences (GlobeNewswire Inc., 2026-02-04)
- Earnings releases for Q1 and Q2 (no specific dates available)
Market Narrative: The news sentiment has been driving the stock's upward momentum, with the positive headlines reinforcing the uptrend.
Risk & Volatility Assessment
Beta Interpretation: Beta > 1.29 indicates high risk relative to market
Volatility Regime: High volatility, with a Historical Volatility: HV20 35.1% / HV30 39.1% / HV60 52.5%
Options Market Signals:
- IV Rank: 28.1% (Medium - shows if volatility is historically high/low)
- Current IV: 177.0%
- Expected Move: $0.82 (32 DTE), 7-DTE: $1.45
- Volume Flow: 29 calls vs 252 puts
- Open Interest: 29 calls vs 194 puts
Downside Protection: Support levels include SMA 200 at $3.78 and the lower Bollinger Band at $3.39.
Market Context & Positioning
Sector Performance: Relative strength within the sector, with a R-squared value of 0.23 indicating moderate correlation
Institutional Activity: Volume patterns suggest institutional interest, with an average volume flow of 452704.43 and increasing OBV.
Correlation Analysis: Correlation to market is relatively low at 0.23, indicating potential for continued outperformance.
Relative Valuation: The stock is positioned within a trading range, with the upper Bollinger Band serving as resistance.
Key Levels & Action Items
Critical Price Levels:
- SMA 20: $3.68 (resistance)
- SMA 50: $3.70 (resistance)
- SMA 200: $3.78 (support)
- Upper Bollinger Band: $3.96
Breakout/Breakdown Levels:
- SMA 200 at $3.78
- Lower Bollinger Band at $3.39
Time-Sensitive Catalysts:
- Upcoming Investor Conferences (GlobeNewswire Inc., 2026-02-04)
- Earnings releases for Q1 and Q2 (no specific dates available)
Risk Management: Stop-loss levels should be set around the SMA 200 at $3.78, with position sizing considerations taken into account.
Analysis Summary:
SABS presents a compelling investment opportunity due to its strong technical momentum, positive news sentiment, and potential for future growth. However, high volatility and regulatory risks must be carefully managed. The stock is positioned within a trading range, with the upper Bollinger Band serving as resistance. Key levels include SMA 20 at $3.68 (resistance), SMA 200 at $3.78 (support), and the lower Bollinger Band at $3.39.
Generated
News
All SABS news →
SABS Options Activity & IV Rank
SABS IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 121.8%
7-DTE IV: 228.0%
Expected Move: $8.72
7-DTE Move: $0.85
Days to Exp: 39 (2026-12-18)
Options Flow · All expiries
Call Volume: 301
Put Volume: 152
P/C Volume: 0.505
BULLISH
Call OI: 3,513
Put OI: 986
P/C OI: 0.281
Total OI: 4,499
ATM Options Pricing
ATM Call: $1.23
ATM Put: $7.50
Call %: 39.4%
Put %: 241.2%
Chain Summary
Chain Volume: 453
Chain OI: 4,499
Last Updated: 11/9/2026
Spread Scanner
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Scanning bull put, bear call, iron condor and calendar spreads…
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 42nd percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
42%
vs own history
GEX tilt
+0.21
OI-weighted, today
Vanna tilt
-0.52
δ-sensitivity to IV
Charm tilt
-0.02
δ-decay vs time
Vanna tilt -0.52: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably if implied volatility changed.
? What is this?
· 5 ATM contracts, 1k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
No data
30 DTE / 10d
—
—
pts
EXTREME
No data
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Loading the implied volatility surface…
Volatility Smile
Loading the implied volatility smile…
IV Rank (7 DTE)30.3MediumNov 9
IV Rank (30 DTE)20.8LowNov 9
Straddle Price (30 DTE)$8.72Nov 9
Beta Analysis
Risk Metrics
Beta: 1.0490
Alpha: 2.52%
Correlation: 0.2340
R-Squared: 5.5%
Stock Volatility: 61.8%
Market Volatility: 13.8%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Above average volatility - stock moves with market amplification
Above average volatility - stock moves with market amplification
Beta & Alpha Over Time
Notable investors who own SABS
2 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Millennium Management Hedge fund Izzy Englander | $10.7M | #1528 of 3716 | -9.4% | 13F | |
| Citadel Hedge fund Ken Griffin | $245K | #5275 of 6285 | new | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
SABS Institutional Ownership (13F)
Filings for 2026-06-30 · 23 already for 2026-09-30
? 13F Guide
Diluted shares outstanding: 68,128,798 (as of 2026-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
5 filers$724.62K notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Citadel Advisors LLC Custodian | $315.90K | 43.59% | 2026-06-30 |
| 2 | Jane Street Group, LLC Custodian | $209.04K | 28.85% | 2026-06-30 |
| 3 | Susquehanna International Group, LLP Custodian | $110.76K | 15.29% | 2026-06-30 |
| 4 | GROUP ONE TRADING LLC Custodian | $78.78K | 10.87% | 2026-06-30 |
| 5 | Simplex Trading, LLC Custodian | $10.14K | 1.40% | 2026-09-30 |
2 filers$944.21K notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Jane Street Group, LLC Custodian | $883.35K | 93.55% | 2026-06-30 |
| 2 | Simplex Trading, LLC Custodian | $60.86K | 6.45% | 2026-09-30 |
SABS Insider Trading (Form 4)
Latest: 2026-09-18Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-09-18 | Alexandra Kropotova | CHIEF MEDICAL OFFICER | Tax (F) | −473 | — | EDGAR | |
| 2026-06-26 | Alexandra Kropotova | CHIEF MEDICAL OFFICER | Tax (F) | −988 | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
SABS Insider Holdings
1 insider · @ $3.10
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Alexandra Kropotova | CHIEF MEDICAL OFFICER | 41,853 | $129.7K | $0 | 2 | 2026-09-18 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
SABS Board & Officers
As of SEC filings through Sep 18, 2026Directors 16
- David Charles Link · since Oct 22, 2021
- Eddie Joe Sullivan · since Oct 22, 2021
- William James Polvino · since Oct 22, 2021
- Scott Giberson · since Jul 6, 2022
- Erick Lucera · since Apr 3, 2023
- Andrew Moin · since Oct 2, 2023
- John Petry · since Oct 2, 2023
- Sessa Capital (Master), L.P. (entity) · since Oct 2, 2023
- Sessa Capital GP, LLC (entity) · since Oct 2, 2023
- Sessa Capital IM GP, LLC (entity) · since Oct 2, 2023
- Sessa Capital IM, L.P. (entity) · since Oct 2, 2023
- Helen K. Ellias · since Nov 14, 2023
- Jay S Skyler · since May 3, 2024
- David Link · on file since Dec 2025
- David Zaccardelli · since Jan 5, 2026
- Rita Jain · since Jan 5, 2026
Officers 5
- Samuel J Reich · CEO & Executive Chairman · listed since Feb 2024
- Eddie Joe Sullivan · President · listed since Feb 2024
- Lucy To · Chief Financial Officer · since Jul 26, 2024
- Christoph Lawrence Bausch · Chief Operating Officer · listed since Sep 2022
- Alexandra Kropotova · Chief Medical Officer · since Jun 6, 2022
Changes in the last 10 years (62)
| Jan 5, 2026 | Rita Jain became a director |
| Jan 5, 2026 | David Zaccardelli became a director |
| Dec 18, 2025 | David Link first on file as a director |
| Sep 30, 2025 | The company announced the departure of Jeffrey G Spragens from the board in an SEC filing |
| Sep 30, 2025 | The company announced the departure of Christine E Hamilton from the board in an SEC filing |
| Jul 26, 2024 | Lucy To became Chief Financial Officer |
| Jun 4, 2024 | Mark William Conley became Interim Chief Financial Officer, Vice President of Finance |
| May 26, 2024 | The company announced the departure of Michael King as Chief Financial Officer in an SEC filing |
| May 3, 2024 | Jay S Skyler became a director |
| Feb 23, 2024 | Samuel J Reich listed as CEO & Executive Chairman (previously Executive Chairman) in SEC filings |
| Feb 23, 2024 | Eddie Joe Sullivan listed as President (previously Chief Executive Officer) in SEC filings |
| Nov 14, 2023 | Helen K. Ellias became a director |
| Oct 30, 2023 | Michael King became Chief Financial Officer |
| Oct 23, 2023 | The company announced the departure of Russell P Beyer as Chief Financial Officer in an SEC filing |
| Oct 2, 2023 | Sessa Capital IM, L.P. became a director |
| Oct 2, 2023 | Sessa Capital IM GP, LLC became a director |
| Oct 2, 2023 | Sessa Capital GP, LLC became a director |
| Oct 2, 2023 | Sessa Capital (Master), L.P. became a director |
| Oct 2, 2023 | John Petry became a director |
| Oct 2, 2023 | Andrew Moin became a director |
| Apr 3, 2023 | Erick Lucera became a director |
| Mar 16, 2023 | Eddie Joe Sullivan no longer listed as a 10% owner in SEC filings |
| Sep 15, 2022 | Christoph Lawrence Bausch listed as Chief Operating Officer (previously Chief Science Officer) in SEC filings |
| Jul 6, 2022 | Scott Giberson became a director |
| Jun 6, 2022 | Alexandra Kropotova became Chief Medical Officer |
| Dec 31, 2021 | The company announced the departure of Charles Hiram Randall as Chief Strategy Officer in an SEC filing |
| Nov 19, 2021 | Samuel J Reich no longer listed as a 10% owner in SEC filings |
| Nov 19, 2021 | Samuel J Reich listed as Executive Chairman (previously CEO and CFO) in SEC filings |
| Nov 17, 2021 | The company announced the departure of Samuel J Reich from the board in an SEC filing |
| Oct 22, 2021 | William James Polvino became a director |
| Oct 22, 2021 | Thomas Charles Luke became Chief Medical Officer |
| Oct 22, 2021 | The company announced the departure of Stephen D. Collins from the board in an SEC filing |
| Oct 22, 2021 | The company announced the departure of James Joseph Martin from the board in an SEC filing |
| Oct 22, 2021 | The company announced the departure of Ilan Katz from the board in an SEC filing |
| Oct 22, 2021 | Russell P Beyer became Chief Financial Officer |
| Oct 22, 2021 | Mervyn Turner became a director |
| Oct 22, 2021 | Melissa Vera Ullerich became Chief Communications Officer |
| Oct 22, 2021 | Jerry Lynn Pommer became Chief Compliance Officer |
| Oct 22, 2021 | Hua Wu became SVP Research & Product Dev. |
| Oct 22, 2021 | Frederick Finnegan became Chief Business Officer |
| Oct 22, 2021 | Edward D. Hamilton became a 10% owner |
| Oct 22, 2021 | Eddie Joe Sullivan became a director |
| Oct 22, 2021 | Eddie Joe Sullivan became a 10% owner |
| Oct 22, 2021 | Eddie Joe Sullivan became Chief Executive Officer |
| Oct 22, 2021 | David Charles Link became a director |
| Oct 22, 2021 | Christoph Lawrence Bausch became Chief Science Officer |
| Oct 22, 2021 | Christine E Hamilton became a director |
| Oct 22, 2021 | Christine E Hamilton became a 10% owner |
| Oct 22, 2021 | Charles Hiram Randall became Chief Strategy Officer |
| Oct 22, 2021 | Carlos N Carillo became SVP Regulatory Affairs |
| Oct 22, 2021 | Bruce Kipp Erickson became Chief Operating Officer |
| Jan 14, 2021 | Big Cypress Holdings LLC first listed as a director in an SEC filing |
| Jan 14, 2021 | Big Cypress Holdings LLC first listed as CEO and CFO in an SEC filing |
| Jan 11, 2021 | Stephen D. Collins became a director |
| Jan 11, 2021 | Samuel J Reich became a director |
| Jan 11, 2021 | Samuel J Reich became a 10% owner |
| Jan 11, 2021 | Samuel J Reich became CEO and CFO |
| Jan 11, 2021 | Jeffrey G Spragens became a director |
| Jan 11, 2021 | James Joseph Martin became a director |
| Jan 11, 2021 | Ilan Katz became a director |
| Jan 11, 2021 | Ilan Katz became a 10% owner |
| Jan 11, 2021 | Big Cypress Holdings LLC became a 10% owner |
Not reported recently (13)
- Mark William Conley · Last reported as Interim Chief Financial Officer, Vice President of Finance in an SEC filing dated Jun 24, 2024
- Christine E Hamilton · Last reported as a 10% owner in an SEC filing dated Feb 10, 2023
- Frederick Finnegan · Last reported as Chief Business Officer in an SEC filing dated Mar 18, 2022
- Melissa Vera Ullerich · Last reported as Chief Communications Officer in an SEC filing dated Mar 18, 2022
- Thomas Charles Luke · Last reported as Chief Medical Officer in an SEC filing dated Mar 18, 2022
- Jerry Lynn Pommer · Last reported as Chief Compliance Officer in an SEC filing dated Mar 18, 2022
- Bruce Kipp Erickson · Last reported as Chief Operating Officer in an SEC filing dated Mar 18, 2022
- Edward D. Hamilton · Last reported as a 10% owner in an SEC filing dated Oct 26, 2021
- Carlos N Carillo · Last reported as SVP Regulatory Affairs in an SEC filing dated Oct 26, 2021
- Hua Wu · Last reported as SVP Research & Product Dev. in an SEC filing dated Oct 26, 2021
- Mervyn Turner · Last reported as a director in an SEC filing dated Oct 26, 2021
- Ilan Katz · Last reported as a 10% owner in an SEC filing dated Oct 15, 2021
- Big Cypress Holdings LLC · Last reported as a 10% owner in an SEC filing dated Jan 14, 2021
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
Recent SEC Filings
Latest: 2026-11-05
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
| Filing Date | Accession | Link |
|---|
ETF Holders
18 ETFs hold SABS
18 shown · $18.04M total exposure · 0.01% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $7.2M | — | 2026-09-30 |
| 2 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.01% | $4.0M | $76.6B | 2026-11-06 |
| 3 | VXF Vanguard Extended Market ETF | Vanguard | 0.00% | $2.4M | — | 2026-09-30 |
| 4 | IWN iShares Russell 2000 Value ETF | iShares (BlackRock) | 0.01% | $1.5M | $13.9B | 2026-11-06 |
| 5 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.01% | $1.0M | — | 2026-09-30 |
| 6 | IWC iShares Micro-Cap ETF | iShares (BlackRock) | 0.04% | $509,298 | $1.2B | 2026-11-06 |
| 7 | SURI Simplify Propel Opportunities ETF | Nport | 0.53% | $408,911 | — | 2026-06-30 |
| 8 | SBIO ALPS Medical Breakthroughs ETF | Nport | 0.15% | $351,077 | — | 2026-08-31 |
| 9 | AVSC Avantis U.S. Small Cap Equity ETF | Avantis | 0.01% | $340,664 | $3.2B | 2026-11-05 |
| 10 | VTWV Vanguard Russell 2000 Value ETF | Vanguard | 0.01% | $161,112 | — | 2026-09-30 |
| 11 | GSSC Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF | Goldman | 0.01% | $129,063 | $1.0B | 2026-11-05 |
| 12 | RSSL Global X Russell 2000 ETF | Global X | 0.01% | $79,365 | — | 2026-11-06 |
| 13 | VTHR Vanguard Russell 3000 ETF | Vanguard | 0.00% | $12,353 | — | 2026-09-30 |
| 14 | ITWO ProShares Russell 2000 High Income ETF | ProShares | 0.01% | $9,414 | — | 2026-11-06 |
| 15 | URTY ProShares UltraPro Russell2000 | ProShares | 0.00% | $7,302 | — | 2026-11-06 |
| 16 | UWM ProShares Ultra Russell2000 | ProShares | 0.00% | $4,969 | — | 2026-11-06 |
| 17 | HDG ProShares Hedge Replication ETF | ProShares | 0.00% | $206 | — | 2026-11-06 |
| 18 | RB ProShares Russell 2000 Dynamic Buffer ETF | ProShares | 0.00% | $55 | — | 2026-11-06 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-1.30
TTM Revenue
—
TTM Net Income
$-38.87M
TTM Op. Cash Flow
$-53.94M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q2 '26 | 2026-06-30 | — | $-22.49M | $-0.28 | $-9.84M |
| Q1 '26 | 2026-03-31 | — | $-18.87M | $-0.35 | $-14.27M |
| Q4 '25 | 2025-12-31 | — | $-2.85M | $-0.46 | $-16.78M |
| Q3 '25 | 2025-09-30 | — | $5.34M | $-0.21 | $-13.05M |
| Q2 '25 | 2025-06-30 | — | $-10.11M | $-1.09 | $-7.15M |
| Q1 '25 | 2025-03-31 | — | $-5.20M | $-0.56 | $-7.80M |
| Q4 '24 | 2024-12-31 | $114.70K | $-11.39M | $-1.23 | $-9.53M |
| Q3 '24 | 2024-09-30 | — | $-10.35M | $-1.12 | $-6.29M |
| Q2 '24 | 2024-06-30 | $263.14K | $-7.34M | $-0.79 | $-7.72M |
| Q1 '24 | 2024-03-31 | $944.58K | $-5.03M | $-0.54 | $-10.75M |
| Q4 '23 | 2023-12-31 | $305.01K | $-22.86M | $-3.85 | $-13.45M |
| Q3 '23 | 2023-09-30 | $1.27M | $-5.10M | $-0.97 | $-5.17M |
Q2 2026 • period ending 2026-06-30 • filed 2026-08-06
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
0.98
P/S
—
EV/EBITDA
—
EV/Sales
—
ROE
-18.1%
ROA
-16.3%
Div Yield
0.00%
FCF Yield
-25.50%
Debt/Equity
0.01
Current Ratio
—
Market Cap
$211.54M
as of 2026-11-09
SABS vs Peers
Related companies, largest first| Company | Market cap | P/E | Revenue growth | YTD | IV rank |
|---|---|---|---|---|---|
| CORT Corcept Therapeutics Inc. | $7.9B | 59.5 | +30.0% | +97.7% | 100 |
| CLDX Celldex Therapeutics, Inc | $2.3B | — | −93.9% | +16.3% | 10 |
| CMPS COMPASS Pathways Plc American Depository | $1.2B | — | — | +40.5% | 25 |
| ACHV Achieve Life Sciences, Inc. | $693M | — | — | +35.0% | 47 |
| DCTH Delcath Systems Inc | $518M | 1953.0 | +35.8% | +96.3% | 11 |
| PHAT Phathom Pharmaceuticals, Inc. Common Sto | $427M | — | +86.8% | −65.8% | 5 |
| SABS SAB Biotherapeutics, Inc. Common Stock | $273M | — | — | −17.8% | 21 |
| ABEO Abeona Therapeutics Inc. Common Stock | $238M | — | +6280.0% | −50.6% | 30 |
| MIST Milestone Pharmaceuticals Inc. Common Sh | $95M | — | — | −61.5% | — |
| Peer median | $605M | 1006.2 | +35.8% | +25.6% | 25 |
P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
4.80M
SI % of Float
6.18%
Days to Cover
6.93
Short Vol Ratio
67.5%
Free Float
77.74M
Float %
85.4%
Short interest 2026-10-15 • Short volume 2026-11-06 • Float 2026-08-14